Clinical trial · no report yet · Phase 3

BioFront

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

NCT07383441 ↗
Recruiting
SWOG Cancer Research Network
Deep

We haven't built an HCP commentary report on BioFront (axitinib, cabozantinib and 6 more in Advanced Clear Cell Renal Cell Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on BioFront so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Channel	Indexed
X threads	18
YouTube	3
Podcasts	2

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: Phase III Double Blinded Trial of Immune-Based Therapy With a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial]
Phase: Phase 3
Status: Recruiting
Conditions: Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
Interventions: Axitinib; Biospecimen Collection; Bone Scan; Cabozantinib; Clostridium butyricum CBM 588 Probiotic Strain; Computed Tomography; Ipilimumab; Lenvatinib; Magnetic Resonance Imaging; Nivolumab; Nivolumab and Recombinant Human Hyaluronidase; Pembrolizumab; Placebo Administration
Arms: Arm 1 (MO-03, SOC immunotherapy) · Experimental
Arm 2 (placebo, SOC immunotherapy) · Placebo comparator
Enrollment: 718 (estimated)
Primary outcomes: Progression-free survival (PFS)
Sponsor: SWOG Cancer Research Network with National Cancer Institute (NCI)
Start: Jun 5, 2026
Primary completion: Jan 31, 2033 (estimated)
Results posted: No
Registry record: NCT07383441 · updated Jun 11, 2026